ReviewFrontiers in pharmacology2026
Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a leading cause of preventable blindness globally, diabetic retinopathy (DR) requires innovative treatments beyond conventional anti-VEGF therapies, which face limitations in efficacy, administration burden, and multifactorial targeting. Plant-derived bioactive metabolites (e.g., quercetin, puerarin) have been reported to modulate multiple DR-relevant pathways in preclinical studies against DR pathogenesis, including modulation of angiogenesis, oxidative stress, and inflammation. However, their clinical translation is hindered by compound- and route-dependent pharmacokinetic challenges, including poor solubility, extensive metabolism, rapid ocular clearance, and restricted posterior-segment exposure. This review explores nanomaterial-enabled delivery systems to overcome these barriers, detailing platforms such as polymeric nanoparticles, lipid-based carriers, and exosomes engineered to enhance solubility, penetration, and sustained release. Key strategies including barrier-specific size optimization, surface engineering, and ligand functionalization are critically analyzed. Integrated preclinical frameworks utilizing
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.